Therapy Areas: Infectious Diseases
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation fo...
Lakewood-Amedex Biotherapeutics to present at H.C. Wainwright 28th Annual Global Investment Conference
9 September 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) announced on Tuesday that its CEO, Kelvin Cooper, Ph.D., will deliver a virtual presentation a...
Immuron signs US distribution deal for PROIBS
4 September 2026 - Australian biopharmaceutical company Immuron Limited (ASX: IMC; NASDAQ: IMRN), which develops and commercialises targeted polyclonal antibodies for infectious diseases, announced on...
Cepheid's Xpert Hemorrhagic Fever Panel test granted WHO Emergency Use Listing to support DRC Ebola outbreak response
4 September 2026 - Molecular diagnostics company Cepheid, a Danaher (NYSE:DHR) company, announced on Thursday that it has received Emergency Use Listing (EUL) from the World Health Organization (WHO) ...
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
20 August 2026 - Pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL) and Medigen Vaccine Biologics Corp (MVC), a developer of vaccines for infectious dise...
Amplitude Therapeutics and Lilly collaborate on trans-amplifying RNA vaccine development for infectious diseases
20 August 2026 - Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, announced on Wednesday a strategic research collaboration and licensing...